# JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

> **NCT06838338** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jian Li** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** JAB-21822
- **DRUG:** standard second-line chemotherapy
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06838338
- **Lead sponsor:** Jian Li
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2026-03
- **Final completion:** 2026-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06838338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06838338, "JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06838338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*